81 filings
6-K
OKYO
OKYO Pharma Ltd
8 May 24
OKYO Pharma Announces Participation in May 2024 Investor Conferences
7:00am
6-K
OKYO
OKYO Pharma Ltd
30 Apr 24
Current report (foreign)
7:00am
6-K
OKYO
OKYO Pharma Ltd
8 Apr 24
Current report (foreign)
7:00pm
6-K
OKYO
OKYO Pharma Ltd
4 Apr 24
Current report (foreign)
6:30am
6-K
OKYO
OKYO Pharma Ltd
2 Apr 24
Current report (foreign)
7:00am
6-K
e8ulg o7e
29 Mar 24
Current report (foreign)
2:30pm
6-K
578nej6h s7y8v4fta
22 Mar 24
Current report (foreign)
7:00am
6-K
myjnj7j
21 Mar 24
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
7:00am
6-K
zuelp vncdx7m6iol
20 Mar 24
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
8:07am
6-K
9paai2ig9
9 Feb 24
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
7:00am
6-K
5u4cxy ng5mgm9
31 Jan 24
Current report (foreign)
7:00am
6-K
plupq544h2r0 3t1
8 Jan 24
Current report (foreign)
7:00am
6-K
r7v6rj2voe5te6sm
5 Jan 24
Current report (foreign)
9:30am
6-K
37g4j7kr4jrkpyxx
21 Dec 23
Current report (foreign)
7:35am
6-K
yf860
18 Dec 23
Current report (foreign)
4:56pm
6-K
3bu17ehj3ap
4 Dec 23
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
7:00am
6-K
d6hl8w
29 Nov 23
Current report (foreign)
7:00am
6-K
bofhj wiwal1
1 Nov 23
Current report (foreign)
4:55pm
6-K
yopyzccq
31 Oct 23
OKYO Pharma Announces $5.84 Million cash raise and payables reduction
7:00am
6-K
w4ep1 qsp
10 Oct 23
Current report (foreign)
7:00am